CN1612733A - 用作蛋白激酶抑制剂的苯并咪唑类 - Google Patents

用作蛋白激酶抑制剂的苯并咪唑类 Download PDF

Info

Publication number
CN1612733A
CN1612733A CNA028270002A CN02827000A CN1612733A CN 1612733 A CN1612733 A CN 1612733A CN A028270002 A CNA028270002 A CN A028270002A CN 02827000 A CN02827000 A CN 02827000A CN 1612733 A CN1612733 A CN 1612733A
Authority
CN
China
Prior art keywords
alkyl
optional
amino
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028270002A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·赛温
李劲波
格雷戈里·P·罗思
克里斯托弗·R·萨科
罗杰·J·斯诺
诺埃尔·S·威尔森
史蒂文·S·普伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of CN1612733A publication Critical patent/CN1612733A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA028270002A 2001-11-09 2002-11-05 用作蛋白激酶抑制剂的苯并咪唑类 Pending CN1612733A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34463601P 2001-11-09 2001-11-09
US60/344,636 2001-11-09

Publications (1)

Publication Number Publication Date
CN1612733A true CN1612733A (zh) 2005-05-04

Family

ID=23351329

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028270002A Pending CN1612733A (zh) 2001-11-09 2002-11-05 用作蛋白激酶抑制剂的苯并咪唑类

Country Status (18)

Country Link
US (1) US6825219B2 (enExample)
EP (1) EP1448199A1 (enExample)
JP (1) JP2005509003A (enExample)
KR (1) KR20040063144A (enExample)
CN (1) CN1612733A (enExample)
BR (1) BR0214019A (enExample)
CA (1) CA2464419A1 (enExample)
CO (1) CO5580788A2 (enExample)
EA (1) EA200400595A1 (enExample)
HR (1) HRP20040416A2 (enExample)
IL (1) IL161516A0 (enExample)
MX (1) MXPA04004301A (enExample)
NO (1) NO20041887L (enExample)
NZ (1) NZ533310A (enExample)
PL (1) PL369771A1 (enExample)
WO (1) WO2003041708A1 (enExample)
YU (1) YU37904A (enExample)
ZA (1) ZA200402947B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
CN114591333A (zh) * 2020-12-04 2022-06-07 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023131333A1 (zh) * 2022-01-10 2023-07-13 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
FR2851563B1 (fr) * 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2862971B1 (fr) * 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US20050176792A1 (en) * 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2006068105A1 (ja) * 2004-12-20 2006-06-29 Santen Pharmaceutical Co., Ltd. 角結膜障害治療剤
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
EP1879881A2 (en) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
GB0515025D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007058832A2 (en) * 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
US20110071130A1 (en) * 2006-05-08 2011-03-24 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2716599A1 (en) * 2008-02-25 2009-09-03 Lars Thore Burgdorf Glucokinase activators
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
CA2758961A1 (en) 2009-04-27 2010-11-04 High Point Pharmaceuticals, Llc Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as .beta.-secretase inhibitors
US8450354B2 (en) 2010-03-23 2013-05-28 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
US20150152083A1 (en) * 2012-06-06 2015-06-04 Irm Llc, A Delaware Limited Liability Company Compounds and Compositions for Modulating EGFR Activity
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2015083059A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Forms of the egfr inhibitor
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
KR101560338B1 (ko) 2014-04-21 2015-10-19 건국대학교 산학협력단 야누스 키나아제 1의 활성을 선택적으로 저해하는 벤조이미다졸 유도체
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
JP7313364B2 (ja) 2018-02-21 2023-07-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
US12522615B2 (en) 2019-06-24 2026-01-13 Boehringer Ingelheim International Gmbh Macrocyclic compounds and derivatives as EGFR inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) * 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
US4139626A (en) 1976-03-19 1979-02-13 Syntex (U.S.A.) Inc. Anthelmintic 5(6)-benzene ring substituted benzimidazole-2-carbamates
US4191764A (en) 1976-03-19 1980-03-04 Syntex (U.S.A.) Inc. 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
CA1094061A (en) 1976-03-19 1981-01-20 Colin C. Beard 5(6)-benzene ring substituted benzimidazole-2- carbamate derivatives having anthelmintic activity
US4312873A (en) 1978-09-29 1982-01-26 Syntex (U.S.A.) Inc. 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
WO1990002746A1 (en) 1988-09-12 1990-03-22 The Upjohn Company Novel cc-1065 analogs having two cpi subunits
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9107398D0 (en) 1991-04-09 1991-05-22 British Bio Technology Compounds
JP2729545B2 (ja) 1991-06-05 1998-03-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法
US5616537A (en) 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
AU675680B2 (en) 1992-10-14 1997-02-13 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
DE60014130T2 (de) * 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
WO2001070705A1 (en) 2000-03-17 2001-09-27 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US6903126B2 (en) 2001-07-09 2005-06-07 Schering Ag 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
TWI650319B (zh) * 2012-06-06 2019-02-11 諾華公司 用於調節表皮生長因子受體（ｅｇｆｒ）活性之化合物及組合物
WO2015081463A1 (en) * 2013-12-02 2015-06-11 Novartis Ag Egfr inhibitor forms
CN114591333A (zh) * 2020-12-04 2022-06-07 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
CN114591333B (zh) * 2020-12-04 2023-08-01 广州嘉越医药科技有限公司 一种吡咯并嘧啶类化合物的制备方法
WO2023131333A1 (zh) * 2022-01-10 2023-07-13 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途

Also Published As

Publication number Publication date
MXPA04004301A (es) 2004-08-11
NO20041887L (no) 2004-05-07
EA200400595A1 (ru) 2004-10-28
BR0214019A (pt) 2004-10-13
PL369771A1 (en) 2005-05-02
IL161516A0 (en) 2004-09-27
KR20040063144A (ko) 2004-07-12
CO5580788A2 (es) 2005-11-30
HRP20040416A2 (en) 2005-04-30
EP1448199A1 (en) 2004-08-25
YU37904A (sh) 2006-08-17
CA2464419A1 (en) 2003-05-22
JP2005509003A (ja) 2005-04-07
NZ533310A (en) 2004-12-24
ZA200402947B (en) 2005-01-24
WO2003041708A1 (en) 2003-05-22
US6825219B2 (en) 2004-11-30
US20030144281A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
US6825219B2 (en) Substituted benzimidazole compounds
CN1099413C (zh) 某些稠合n－吡咯甲酰苯胺;一类新的脑gaba受体配体
US7138420B2 (en) Substituted benzimidazole compounds
CN1261098C (zh) p38－α激酶的抑制剂
CN1259315C (zh) Mcp－1功能的拮抗物及其应用方法
CN1376063A (zh) 环胺ccr3拮抗剂
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
CN1261877A (zh) 4－溴或4－碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
WO2005079791A1 (en) Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
CN1323307A (zh) 1h－咪唑并吡啶衍生物
CN1265649A (zh) 作为mcp－1受体拮抗剂的吲哚衍生物
CN1265033A (zh) 二芳基咪唑衍生物:新的一类npy特异性配体
JP2017504635A (ja) 化合物
JP2007502842A (ja) ケモカインレセプター活性のモジュレータとしての置換シクロアルキルアミン誘導体
CN1608050A (zh) 哌嗪衍生物
CN1675170A (zh) 酰化的芳基环烷基胺和它们作为药物的用途
CN1496257A (zh) 调控免疫球蛋白e及抑制细胞增殖的苯并咪唑化合物
CN1832930A (zh) 酰胺衍生物
AU2012210718B2 (en) Pyrazole compounds as CRTH2 antagonists
CN1729173A (zh) N－(吲哚乙基)环胺化合物
CN1512985A (zh) 氨基喹啉和氨基哌啶衍生物和它们的作为腺苷a3配体的应用
US20050176792A1 (en) Ketone substituted benzimidazole compounds
CN1202106A (zh) 选择性的β3肾上腺素能激动剂
CN1310909C (zh) 新型杂芳基衍生物、其制备以及应用
CN1966506A (zh) 吡唑并嘧啶酮衍生物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1073791

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1073791

Country of ref document: HK